What We Do

HomeWhat We Do ▶ Meet Andrew Tager
Meet Andrew Tager

Andrew Tager

Andrew Tager, MD, of Massachusetts General Hospital is a 2008 recipient of the ATS Foundation/Coalition for Pulmonary Fibrosis Partnership Grant in Pulmonary Fibrosis.

With his research grant, Dr. Tager studies the role of lysophosphatidic acid in pulmonary fibrosis.

“The ATS award allowed me to do critical initial work that then turned into our first publication and my first R01 award,” says Dr. Tager. “Subsequently we have found that it’s been a very productive area of study, which has led to the identification of one LPA’s receptors as a potential target for drug therapies for idiopathic pulmonary fibrosis.”

Concerned with the impact government cutbacks are having on medical research, Dr. Tager believes it is important that those who benefited from research awards early in their careers consider giving back.

“I feel passionately that deserving young investigators should be afforded the same opportunity that this grant afforded me,” says Dr. Tager.

Update: Today, a pharmaceutical company has been running a Phase II trial of an LPA1 antagonist in idiopathic pulmonary fibrosis generated by Dr. Tager’s work as a research awardee!

The ATS supports the ATS Foundation’s administrative expenses, assuring that every dollar contributed goes directly to support programs.